Events

DESCRIPTION

The National Drug Abuse Treatment Clinical Trials Network WEB-TX study is one of the largest randomized controlled trials to date examining the effectiveness of an internet-delivered treatment intervention on clinical outcomes among people receiving outpatient substance abuse treatment. In addition to the primary outcome analysis showing significant improvements in abstinence and treatment retention among people randomized to the internet-delivered treatment arm, the study has produced three methodological publications, four baseline publications, five secondary outcome publications, and an additional seven secondary outcome publications under review or in preparation. The purpose of this one-hour webinar is to present a synthesis of WEB-TX study findings, focusing on key secondary clinical outcomes, and discuss new areas of research for technology-based treatments for substance use disorders.

LEARNING OBJECTIVES

• Understand the design and methodological decisions critical to the implementation of an effectiveness trial of a technology-based intervention.
• Review the primary outcomes and key secondary outcomes of the WEB-TX study.
• Discuss new areas of research for technology-based interventions.

TARGET AUDIENCE

Everyone is welcome! This webinar is targeted to investigators, research staff, and community providers interested in technology-based interventions for substance use disorders.

About the Presenters

Edward V. Nunes Jr., MD
Dr. Nunes is a Professor of Psychiatry and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatment settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/New York State Psychiatric Institute’s Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

Aimee Campebll, PhD

Aimee Campbell, PhD, is a Research Scientist in the Substance Abuse Division of the New York State Psychiatric Institute (NYSPI) and an Assistant Professor of Clinical Psychiatric Social Work in the Department of Psychiatry at the Columbia University Medical Center. She was the Project Director for the NIDA Clinical Trials Network 0044 study. Her research interests center on the development and testing of behavioral interventions for substance use disorders and HIV prevention and treatment, including through use of technology-based platforms, with a specific emphasis on methods to improve access to and implementation of science-based treatments. Dr. Campbell’s work incorporates the personal, interpersonal, and social contexts in which individuals manage the overlapping challenges of addiction, trauma, mental health disorders, and HIV sexual and drug risk behaviors. She has extensive experience in the development, implementation, and oversight of large community-based clinical trials. She has been involved in treatment research for substance use disorders, primarily in community settings and in partnership with community providers and consumers, for 20 years. Dr. Campbell completed undergraduate training in sociology at the University of Washington and received her master’s degree and doctorate from Columbia University School of Social Work.